Hillevax Inc

NASDAQ HLVX

Download Data

Hillevax Inc Gross Working Capital 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Hillevax Inc Gross Working Capital 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Gross working capital is a financial metric that represents the amount of a company's current assets available to cover its current liabilities and short-term debt obligations. It is calculated by subtracting the sum of current liabilities and short-term debt from the total current assets of a company. Gross working capital provides insights into a company's short-term liquidity and its ability to meet its financial obligations in the near future. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Hillevax Inc Gross Working Capital for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 1.13 B, a 285.30% change year over year.
  • Hillevax Inc Gross Working Capital for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -607.94 M.
NASDAQ: HLVX

Hillevax Inc

CEO Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date April 29, 2022
Location United States
Headquarters 75 State Street, Boston, MA, United States, 02109
Employees 90
Sector Healthcare
Industry Biotechnology
Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

ELYM

Eliem Therapeutics Inc

NA

NA

MNOV

MediciNova Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

VIGL

Vigil Neuroscience Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

CNTA

Centessa Pharmaceuticals PLC ADR

NA

NA

STRO

Sutro Biopharma

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email